Trial Profile
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs MVAME 03 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2016 New trial record